Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMaT trial for Mycobacterium abscessus pulmonary disease
2020-000050-10Phase 2Active
- Sponsor
- The University of Queensland
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amikacin, tigecycline, imipenem, cilastatin, cefoxitin and 10 more in Mycobacterium abscessus lung disease and Mycobacterium abscessus disease, sponsored by The University of Queensland. Primary endpoints: Primary objective endpoint, Short intensive therapy endpoint and 1 more. Started Dec 2021; status: active.
02
Drugs
amikacintigecyclineimipenemcilastatincefoxitin
03
Conditions
Mycobacterium abscessus lung diseaseMycobacterium abscessus disease
Beyond the preview
Go deeper on 2020-000050-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000050-10.